

InnoCan Pharma

15:47 05 Nov 2019

Israeli cannabis companies flower on the Canadian Securities Exchange

The Canadian Securities Exchange (CSE) is becoming increasingly popular with companies that are operating in Israel's emerging cannabis sector.

In a statement, the CSE revealed Tuesday that three Israel-based cannabis companies including InnoCan Pharma Corp (CSE:INNO), Isracann Biosciences Inc (CSE:IPOT), and IM Cannabis Corp (CSE:IMCC) listed on the CSE over the past six weeks.

This represents the CSE's first listings from companies in Israel and is a result of a concerted push over the past two years to woo Israeli entrepreneurs eyeing a Canadian listing.

READ: CSE reports record-setting quarter; hits 500 issuers

"We are delighted to welcome these three companies," said Canadian Securities Exchange CEO Richard Carleton in a statement.

"Israeli cannabis firms typically have a deep portfolio of intellectual property and are building access to the emerging European cannabis market. Many of these companies have a strong need to access the public capital markets for growth funding. The CSE can play a key role in helping them achieve their objectives," he added.

The CSE's rapidly growing stock exchange is focused on working with entrepreneurs to access the capital markets in Canada and internationally. Its efficient operating model and low fee structure help companies minimize their costs and maximize access to liquidity.

"We have established the CSE as the 'go-to' exchange for companies in the Israeli cannabis industry," said Carleton.

"Our international outreach efforts are continuing, not just in Israel but also across Europe, Asia, South America and the Caribbean," he added.

The CSE has seen a rapid increase in issuers, hitting 500 in the first quarter of 2019, a jump of 47.5% compared to the first quarter of 2018. Its issuers, which are active in diverse industries such as cannabis, technology and mining, have raised more than C\$4.2 billion in the last 12 months

The exchange was founded in 2004 and has corporate offices in Toronto, Ontario and Vancouver, British Columbia.


Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Price: 0.12

Market Cap: \$17.26 m

1 Year Share Price Graph



Share Information

Code: INNO

Listing: CSE

| 52 week | High | Low |
|---------|------|------|
| | 0.4 | 0.09 |

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).